Trial reportScientific reports2021
A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Low-Volume Plasma Exchange for Fulminant Hepatic Failure Secondary to Hepatitis A in a Young Adult: A Case Report.Clinical case reports · 2026Article
- Elevated FDP levels independently predict poor outcomes in HBV-ACLF patients treated with artificial liver support system therapy.Scientific reports · 2025Article
- Impact of artificial liver plasma perfusion combined with plasma exchange therapy on clinical efficacy and short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure with or without HIV infection.BMC infectious diseases · 2025Article
- Association between volume of processed plasma and total bilirubin reduction during plasma adsorption for severe liver disease.European journal of medical research · 2025Observational
- Machine learning-based algorithms for the prediction of 90-day survival in patients with liver failure receiving artificial liver therapy.Frontiers in physiology · 2025Article
- Construction of a novel prognostic scoring model for HBV-ACLF liver failure based on dynamic data.Scientific reports · 2024Article
- Review
- Outcome of patients with different stages of acute-on-chronic liver failure treated with artificial liver support system.Frontiers in medicine · 2024Article
- Development and validation of a machine learning model to predict prognosis in liver failure patients treated with non-bioartificial liver support system.Frontiers in medicine · 2024Article
- Analysis of Efficacy and Safety of Small-Volume-Plasma Artificial Liver Model in the Treatment of Acute-On-Chronic Liver Failure.Physiological research · 2023Article
- [Research progress of non-biological artificial liver support system therapy for paitents with liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Association of direct bilirubin to total bilirubin ratio with 90-day mortality in patients with acute-on-chronic liver failure.Frontiers in medicine · 2023Article
- A multi-subgroup predictive model based on clinical parameters and laboratory biomarkers to predict in-hospital outcomes of plasma exchange-centered artificial liver treatment in patients with hepatitis B virus-related acute-on-chronic liver failure.Frontiers in cellular and infection microbiology · 2023Article
- Lower level of IL-28A as a predictive index of the artificial liver support system in effective treatment of patients with HBV-ACLF.Journal of clinical laboratory analysis · 2022Article
- [Assessment Value of Short-Term Prognosis of Six Predictive Models for Patients with Acute-on-Chronic Liver Failure Treated with Artificial Liver Support System].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial liver support system (ALSS) therapy is widely used in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). We aimed to develop a predictive score to identify the subgroups who may benefit from plasma exchange (PE)-centered ALSS therapy. A total of 601 patients were retrospectively enrolled and randomly divided into a derivation cohort of 303 patients and a validation cohort of 298 patients for logistic regression analysis, respectively. Five baseline variables, including liver cirrhosis, total bilirubin, international normalized ratio of prothrombin time, infection and hepatic encephalopathy, were found independently associated with 3-month mortality. A predictive PALS model and the simplified PALS score were developed. The predicative value of PALS score (AUROC = 0.818) to 3-month prognosis was as capable as PALS model (AUROC = 0.839), R score (AUROC = 0.824) and Yue-Meng' score (AUROC = 0.810) (all p > 0.05), and superior to CART model (AUROC = 0.760) and MELD score (AUROC = 0.765) (all p < 0.05). The PALS score had significant linear correlation with 3-month mortality (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.